var data={"title":"Olanzapine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Olanzapine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6676?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=olanzapine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Olanzapine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=olanzapine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Olanzapine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46537504\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Atypical Antipsychotics Safety Review</span>\n      <span class=\"collapsible-date\">September 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Health Canada has reviewed the potential risk of sleep walking and sleep-related eating disorder with the use of atypical antipsychotics and concluded there is a link between these adverse reactions and the use of these medications. Health Canada has recommended to update the product safety information for all atypical antipsychotics to include these adverse reactions.</p>\n        <p style=\"text-indent:0em;\">Further information may be found at https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/atypical-antipsychotics-assessing-potential-risk-sleep-walking-sleep-related-eating-disorder.html.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709177\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Increased mortality in elderly patients with dementia-related psychosis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration, 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients between 1.6 and 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was approximately 4.5%, compared with a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patient is not clear. Olanzapine is not approved for treatment of patients with dementia-related psychosis.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Postinjection delirium/sedation syndrome (Zyprexa Relprevv): </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Adverse reactions with signs and symptoms consistent with olanzapine overdose, in particular, sedation (including coma) and/or delirium, have been reported following injections of olanzapine extended release (ER). Olanzapine ER must be administered in a registered health care facility with ready access to emergency response services. After each injection, patients must be observed at the health care facility by a health care provider for at least 3 hours. Because of this risk, olanzapine ER is available only through a restricted distribution program called Zyprexa Relprevv Patient Care Program, and requires health care provider, health care facility, patient, and pharmacy enrollment.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26715078\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>ZyPREXA;</li>\n      <li>ZyPREXA Relprevv;</li>\n      <li>ZyPREXA Zydis</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203157\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>ACT Olanzapine;</li>\n      <li>ACT Olanzapine ODT;</li>\n      <li>Apo-Olanzapine;</li>\n      <li>Apo-Olanzapine ODT;</li>\n      <li>Auro-Olanzapine ODT;</li>\n      <li>JAMP Olanzapine FC;</li>\n      <li>JAMP-Olanzapine ODT;</li>\n      <li>Mar-Olanzapine;</li>\n      <li>Mar-Olanzapine ODT;</li>\n      <li>Mint-Olanzapine ODT;</li>\n      <li>Mylan-Olanzapine;</li>\n      <li>Mylan-Olanzapine ODT;</li>\n      <li>Olanzapine for injection;</li>\n      <li>Olanzapine ODT;</li>\n      <li>PHL-Olanzapine;</li>\n      <li>PHL-Olanzapine ODT;</li>\n      <li>PMS-Olanzapine;</li>\n      <li>PMS-Olanzapine ODT;</li>\n      <li>RAN-Olanzapine;</li>\n      <li>RAN-Olanzapine ODT;</li>\n      <li>Riva-Olanzapine;</li>\n      <li>Riva-Olanzapine ODT;</li>\n      <li>Sandoz-Olanzapine;</li>\n      <li>Sandoz-Olanzapine ODT;</li>\n      <li>Teva-Olanzapine;</li>\n      <li>Teva-Olanzapine ODT;</li>\n      <li>Van-Olanzapine;</li>\n      <li>Zyprexa;</li>\n      <li>Zyprexa Intramuscular;</li>\n      <li>Zyprexa Zydis</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203198\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antimanic Agent;</li>\n      <li>\n        Second Generation (Atypical) Antipsychotic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203161\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Schizophrenia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Initial: 5 to 10 mg once daily (increase to 10 mg once daily within 5 to 7 days); thereafter, adjust by 5 mg daily at 1-week intervals, up to a recommended maximum of 20 mg/day. Maintenance: 10 to 20 mg once daily. Doses up to 60 mg daily have been used in treatment-resistant schizophrenia; however, supporting evidence is limited (APA [Lehman 2004]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Special risk patients:</i> Initial: 5 mg once daily is recommended in patients who are debilitated, who have a predisposition to hypotensive reactions, who exhibit a combination of factors that may result in slower metabolism of olanzapine (eg, nonsmoking female patients &ge;65 years), or who may be more pharmacodynamically sensitive to olanzapine; increase dose with caution as clinically indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release injection: IM: <b>Note:</b> Establish tolerance to oral olanzapine prior to changing to extended-release injection. Maximum dose: 300 mg every 2 weeks or 405 mg every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Patients established on oral olanzapine 10 mg daily:</i> Initial dose: 210 mg every 2 weeks for 4 doses or 405 mg every 4 weeks for 2 doses; Maintenance dose: 150 mg every 2 weeks or 300 mg every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Patients established on oral olanzapine 15 mg daily:</i> Initial dose: 300 mg every 2 weeks for 4 doses; Maintenance dose: 210 mg every 2 weeks or 405 mg every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Patients established on oral olanzapine 20 mg daily:</i> Initial and maintenance dose: 300 mg every 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Special risk patients:</i> Initial: 150 mg every 4 weeks is recommended in patients who are debilitated, who have a predisposition to hypotensive reactions, who exhibit a combination of factors that may result in slower metabolism of olanzapine (eg, nonsmoking female patients &ge;65 years), or who may be more pharmacodynamically sensitive to olanzapine; increase dose with caution as clinically indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bipolar I (acute mixed or manic episodes:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Monotherapy:</i> Initial: 10 to 15 mg once daily; increase by 5 mg daily at intervals of not less than 24 hours. Maintenance: 5 to 20 mg daily; recommended maximum dose: 20 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Combination therapy </i>(with lithium or valproate): Initial: 10 mg once daily; dosing range: 5 to 20 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Agitation (acute, associated with bipolar disorder or schizophrenia):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Short-acting injection: IM: Initial dose: 10 mg (a lower dose of 5 to 7.5 mg may be considered when clinical factors warrant); additional doses (up to 10 mg) may be considered; however, 2 hours after the initial dose and 4 hours after the second dose should be allowed between doses to evaluate response (maximum total dose: 30 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Special risk patients:</i> Consider a lower dose of 2.5 mg in patients who are debilitated, who have a predisposition to hypotensive reactions, or who may be more pharmacodynamically sensitive to olanzapine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Short-acting injection: IV (off-label route): <b>Note</b>: The IV route has only been studied in emergency departments, where patients can be closely monitored for respiratory depression (Chan 2013; Cole 2017; Martel 2015; Taylor 2017). The World Federation of Societies of Biological Psychiatry (WFSBP) expert consensus panel recommends against the use of intravenous medications in the management of agitation except in cases where there is no alternative (WFSBP [Garriga 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Monotherapy: IV: Initial: 10 mg; may provide two additional 5 mg doses in 5-minute intervals if needed; maximum: 20 mg (Taylor 2017). <b>Note:</b> Lower doses of 5 mg as a single dose have been studied concomitantly with midazolam (Chan 2013), however, concomitant use of parenteral olanzapine and benzodiazepines is not recommended due to potential for excessive sedation and cardiorespiratory depression.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Depression:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Depression associated with bipolar disorder (in combination with fluoxetine):</i> Oral: Initial: 5 mg in the evening; adjust as tolerated to usual range of 5 to 12.5 mg daily. See <b>&quot;Note.&quot;</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment-resistant depression (in combination with fluoxetine):</i> Oral: Initial: 5 mg in the evening; adjust as tolerated to range of 5 to 20 mg daily. See <b>&quot;Note.&quot;</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note (olanzapine/fluoxetine combination [Symbyax]):</b> When using individual components of fluoxetine with olanzapine rather than fixed dose combination product (Symbyax), approximate dosage correspondence is as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Olanzapine 2.5 mg + fluoxetine 20 mg = Symbyax 3/25</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Olanzapine 5 mg + fluoxetine 20 mg = Symbyax 6/25</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Olanzapine 12.5 mg + fluoxetine 20 mg = Symbyax 12/25</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Olanzapine 5 mg + fluoxetine 50 mg = Symbyax 6/50</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Olanzapine 12.5 mg + fluoxetine 50 mg = Symbyax 12/50</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Special risk patients:</i> Initial: 2.5 to 5 mg once daily is recommended in patients who have a predisposition to hypotensive reactions, who have hepatic impairment, who exhibit a combination of factors that may result in slower metabolism of olanzapine (eg, female, elderly, nonsmoking status), or who may be more pharmacodynamically sensitive to olanzapine; increase dose with caution as clinically indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chemotherapy-associated acute and delayed nausea or vomiting, prevention (off-label use):</b> Oral: 10 mg on the day of chemotherapy (day 1) followed by 10 mg once daily days 2 to 4 (in combination with dexamethasone and palonosetron on day 1 only) (Navari 2007; Navari 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chemotherapy-associated breakthrough nausea or vomiting (off-label use):</b> Oral: 10 mg once daily for 3 days (Navari 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Delirium (off-label use):</b> Oral: 5 mg once daily for up to 5 days (NICE 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Delusional infestation (also called delusional parasitosis) (off-label use):</b> Oral: Initial: 2.5 mg once daily; increase gradually based on response and tolerability up to 5 to 10 mg/day. Maximum: 20 mg/day (Freudenmann 2008; Heller 2013). Additional data may be necessary to further define the role of olanzapine in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Post-traumatic stress disorder (off-label use):</b> Oral: Initial: 5 to 10 mg daily; adjust dose based on response and tolerability every 1 to 2 weeks, up to 20 mg daily (Carey 2012; Stein 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tourette syndrome (off-label use):</b> Initial: 2.5 to 5 mg daily; increase gradually based on response and tolerability to a usual dosage range of 2.5 to 20 mg daily (Pringsheim 2012; Roessner 2011). After initial dosage, increments of 2.5 to 5 mg weekly or biweekly were commonly used for dosage adjustments in clinical trials up to a maximum dosage of 20 mg/day (Budman 2001; Onofrj 2000; Stamenkovic 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Discontinuation of therapy</b>: American Psychiatric Association (APA), Canadian Psychiatric Association (CPA), and World Federation of Societies of Biological Psychiatry (WFSBP) guidelines recommend gradually tapering antipsychotics to avoid withdrawal symptoms and minimize the risk of relapse (APA [Lehman 2004]; Cerovecki 2013; CPA [Addington 2005]; WFSBP [Hasan 2012]); risk for withdrawal symptoms may be highest with highly anti-cholinergic or dopaminergic antipsychotics (Cerovecki 2013). When stopping antipsychotic therapy in patients with schizophrenia, the CPA guidelines recommend a gradual taper over 6 to 24 months, and the APA guidelines recommend reducing the dose by 10% each month (APA [Lehman 2004]; CPA [Addington 2005]). Continuing anti-parkinsonism agents for a brief period after discontinuation may prevent withdrawal symptoms (Cerovecki 2013). When switching antipsychotics, 3 strategies have been suggested: cross-titration (gradually discontinuing the first antipsychotic while gradually increasing the new antipsychotic), overlap and taper (maintaining the dose of the first antipsychotic while gradually increasing the new antipsychotic, then tapering the first antipsychotic), and abrupt change (abruptly discontinuing the first antipsychotic and either increasing the new antipsychotic gradually or starting it at a treatment dose). Evidence supporting ideal switch strategies and taper rates is limited, and results are conflicting (Cerovecki 2013; Remington 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203180\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=olanzapine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Olanzapine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bipolar I (acute mixed or manic episodes):</b> Adolescents &ge;13 years: Oral: Initial: 2.5 to 5 mg once daily; adjust by 2.5 to 5 mg daily to target dose of 10 mg daily; dosing range: 2.5 to 20 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Depression associated with bipolar I disorder (in combination with fluoxetine):</b> Children and Adolescents 10 to 17 years: Oral: Initial: 2.5 mg once daily in the evening (in combination with fluoxetine); adjust dose, if needed, as tolerated; safety of doses &gt;12 mg of olanzapine in combination with fluoxetine doses &gt;50 mg has not been studied in pediatrics. Refer to adult dosing for &quot;<b>Note</b>&quot; for olanzapine/fluoxetine combination (Symbyax).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Schizophrenia:</b> Adolescents &ge;13 years: Oral: Initial: 2.5 to 5 mg once daily; adjust by 2.5 to 5 mg daily to target dose of 10 mg daily; dosing range: 2.5 to 20 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chemotherapy-associated breakthrough or refractory nausea or vomiting (off-label use):</b> Infants, Children, and Adolescents: Oral: 0.1 mg/kg/dose once daily (maximum 10 mg/dose); if necessary, may increase to 0.14 mg/kg/dose once daily (maximum 10 mg/dose) (Flank 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tourette syndrome (off-label use):</b> Children and Adolescents: Initial: 2.5 to 5 mg once daily; increase gradually based on response and tolerability to a usual dosage of 2.5 to 12.5 mg once daily (AACAP [Murphy 2013]; Pringsheim 2012). After initial dosage, increments of 2.5 to 5 mg weekly or biweekly were used for dosage adjustments in clinical trials up to a maximum dosage of 20 mg/day (McCracken 2008; Stephens 2004)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203162\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Short-acting IM, Oral: Consider lower starting dose of 2.5 to 5 mg daily for elderly patients; may increase as clinically indicated and tolerated with close monitoring of orthostatic blood pressure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release IM: Consider lower starting dose of 150 mg every 4 weeks for elderly patients; increase dose with caution as clinically indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Delirium (off-label use):</b> Oral: Patients &gt;60 years: Oral: 2.5 mg daily for up to 5 days (NICE 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Psychosis/agitation associated with dementia (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Short-acting IM: Initial dose: 2.5 or 5 mg; up to 2 additional doses of 1.25 or 2.5 mg may be considered, however, at least 2 hours after the initial dose and at least 1 hour after the second dose should be allowed between doses to evaluate response up to a maximum drug exposure of 12.5 mg per episode (Meehan 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Initial: 2.5 to 5 mg daily, if necessary gradually increase based on response and tolerability not to exceed 10 mg daily. In patients without a clinically significant response after 4 weeks, taper and withdraw therapy. In patients with an adequate response, attempt to taper and withdraw therapy within 4 months, unless symptoms recurred with a previous taper attempt. Assess symptoms at least monthly during taper and for at least 4 months after withdrawal of therapy (APA [Reus 2016]; De Deyn 2004; Schneider 2006; Street 2000; Sultzer 2008; Verhey 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203163\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary. Not removed by dialysis. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203164\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling except when used in combination with fluoxetine (as separate components) the initial olanzapine dose should be limited to 2.5 to 5 mg daily. Use with caution (cases of hepatitis and liver injury have been reported with olanzapine use). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26715079\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intramuscular: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ZyPREXA: 10 mg (1 ea) [contains tartaric acid]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Intramuscular: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ZyPREXA Relprevv: 210 mg (1 ea); 300 mg (1 ea); 405 mg (1 ea) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ZyPREXA: 2.5 mg, 5 mg, 7.5 mg, 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ZyPREXA: 15 mg [contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ZyPREXA: 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Disintegrating, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ZyPREXA Zydis: 5 mg, 10 mg, 15 mg, 20 mg [contains aspartame, methylparaben sodium, propylparaben sodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 10 mg, 15 mg, 20 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26730983\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23799571\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874938\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zyprexa and Zyprexa Zydis: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM134700.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+nIf162NgDrXSMpjxmnBPQRbJoH1bIwPN4EPbLUaSXXg==&amp;TOPIC_ID=9716\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM134700.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zyprexa Relprevv: http://pi.lilly.com/us/zyprexa_relprevv.pdf</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203135\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Short-acting injection: May be administered IM or IV (off-label route); do not administer injection subcutaneously. For IM administration, inject slowly, deep into muscle. For off-label IV route, administer by rapid IV push (Taylor 2017). If dizziness and/or drowsiness are noted, patient should remain recumbent until examination indicates postural hypotension and/or bradycardia are not a problem.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended-release injection: <b>For IM gluteal injection only</b>; do not administer IV or subcutaneously. After needle insertion into muscle, aspirate to verify that no blood appears. Do not massage injection site. Use diluent, syringes, and needles provided in convenience kit; obtain a new kit if aspiration of blood occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet: May be administered without regard to meals.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Orally-disintegrating: Remove from foil blister by peeling back (do not push tablet through the foil); place tablet in mouth immediately upon removal; tablet dissolves rapidly in saliva and may be swallowed with or without liquid. May be administered with or without food/meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203134\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Treatment of the manifestations of schizophrenia; treatment of acute or mixed mania episodes associated with bipolar I disorder (as monotherapy or in combination with lithium or valproate); maintenance treatment of bipolar I disorder; in combination with fluoxetine for treatment-resistant or bipolar I depression</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM, extended-release (Zyprexa Relprevv): Treatment of schizophrenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM, short-acting (Zyprexa IntraMuscular): Treatment of acute agitation associated with schizophrenia and bipolar I mania</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25730993\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Chemotherapy-associated acute and delayed nausea or vomiting, prevention (adults); Chemotherapy-associated breakthrough nausea or vomiting (adults); Chemotherapy-associated breakthrough or refractory nausea or vomiting (pediatrics); Delirium; Delusional infestation (also called delusional parasitosis); Psychosis/agitation associated with dementia; Post-traumatic stress disorder; Tourette syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203206\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">OLANZapine may be confused with olsalazine, QUEtiapine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">ZyPREXA may be confused with CeleXA, Reprexain, Zestril, ZyrTEC</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">ZyPREXA Zydis may be confused with Zelapar, zolpidem</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">ZyPREXA Relprevv may be confused with ZyPREXA IntraMuscular</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Antipsychotics are identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older with dementia due to an increased risk of mortality, cerebrovascular accidents (stroke), and a greater rate of cognitive decline with use; avoid antipsychotics for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. Use <i>may be appropriate</i> in geriatric patients with schizophrenia, bipolar disorder, or for short-term use as an antiemetic during chemotherapy. Antipsychotics like olanzapine may have anticholinergic properties. In addition, antipsychotics should be used with caution in older adults due to their potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203123\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Oral:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardiovascular: Orthostatic hypotension (3% to &ge;20%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Drowsiness (dose dependent; adolescents and adults 20% to 39%), extrapyramidal reaction (dose dependent; adults &le;32%; adolescents &le;10%), akathisia (adolescents and adults 3% to 27%), parkinsonian-like syndrome (14% to 20%; includes akinesia, cogwheel rigidity, extrapyramidal syndrome, hypertonia, hypokinesia, maked facies, and tremor), dizziness (adults 11% to 18%; adolescents 7% to 8%), headache (adolescents 17%), fatigue (dose dependent; adolescents and adults 2% to 14%), insomnia (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endocrine &amp; metabolic: Increased serum prolactin (adolescents 47%; adults 30%), weight gain (adults 5% to 6%; has been reported as high as 40%; adolescents 29% to 31%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrointestinal: Increased appetite (adolescents 17% to 29%; adults 3% to 6%), xerostomia (dose dependent; adults 3% to 22%; adolescents 4% to 7%), dyspepsia (adults 7% to 11%; adolescents 3%), constipation (adolescents and adults 4% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hepatic: Increased serum AST (adolescents 28%), decreased serum bilirubin (adolescents 22%), increased serum ALT (&ge;3 x ULN; adolescents and adults 5% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neuromuscular &amp; skeletal: Weakness (dose dependent; 8% to 20%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Miscellaneous: Accidental injury (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardiovascular: Chest pain (3%), peripheral edema (3%), tachycardia (3%), hypertension (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Personality disorder (5% to 8%), abnormal gait (6%), hypertonia (3%), restlessness (adolescents 3%), falling (older adults &ge;2%), articulation impairment (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endocrine &amp; metabolic: Increased gamma-glutamyl transferase (adolescents 10%; adults 2%), increased uric acid (4%), menstrual disease (2%; including amenorrhea, hypomenorrhea, delayed menstruation, oligomenorrhea), breast changes (male and female adolescents &le;2%; including discharge, enlargement, galactorrhea, gynecomastia, lactation disorder)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrointestinal: Abdominal pain (6%; adolescents), vomiting (&le;4%), diarrhea (3%; adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Genitourinary: Urinary incontinence (adults and older adults &ge;2%), sexual disorder (2%; adolescents &le;1%; anorgasmia, delayed ejaculation, erectile dysfunction, changes in libido, abnormal orgasm, sexual dysfunction), urinary tract infection (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hematologic &amp; oncologic: Bruise (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hepatic: Increased liver enzymes (adolescents &le;8%), increased serum alkaline phosphatase (&ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neuromuscular &amp; skeletal: Tremor (4% to 7%; dose dependent), limb pain (adolescents and adults 5% to 6%), arthralgia (adults 5%; adolescents 2%), back pain (5%), muscle rigidity (2%; adolescents), dyskinesia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ophthalmic: Amblyopia (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Respiratory: Rhinitis (7%), cough (6%), nasopharyngitis (adolescents 4%), pharyngitis (4%), epistaxis (adolescents 3%), respiratory tract infection (adolescents 3%), sinusitis (adolescents 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Miscellaneous: Fever (&le;6%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Injection:</b> Frequency not always defined. Unless otherwise noted, adverse events are reported for placebo-controlled trials in adult patients on extended release IM injection (Zyprexa Relprevv). Also refer to adverse reactions noted with oral therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (2% to 3%), hypotension (short-acting solution for IM injection 2%), prolonged Q-T interval on ECG (2%), orthostatic hypotension (short-acting solution for IM injection 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (13% to 18%), sedation (8% to 13%), drowsiness (both IM injection formulations 5% to 6%), akathisia (short-acting solution for IM injection 5%), dizziness (both IM injection formulations 4%), fatigue (3% to 4%), extrapyramidal reaction (solution for IM injection 2% to 4%), abnormality in thinking (3%), auditory hallucination (3%), parkinsonian-like syndrome (short-acting solution for IM injection 3%), restlessness (3%), pain (2% to 3%), abnormal dreams (2%), procedural pain (2%), sleep disorder (2%), dysarthria (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Acne vulgaris (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight gain (6% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (5% to 7%), vomiting (6%), xerostomia (2% to 6%), increased appetite (1% to 6%), nausea (long-acting IM formula 4% to 5%; short-acting solution for injection &lt;1%), tooth infection (4%), toothache (3% to 4%), abdominal pain (3%), flatulence (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Vaginal discharge (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased liver enzymes (3% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Viral infection (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site (both IM injection formulations 1% to 4%), abscess at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (3%), back pain (5%), muscle spasm (1% to 3%), stiffness (4%), tremor (long-acting IM formula 3%; short-acting solution for injection 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Otalgia (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (9%), nasal congestion (7%), nasopharyngitis (3% to 6%), upper respiratory tract infection (3% to 4%), pharyngolaryngeal pain (3%), sneezing (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal distension, accommodation disturbance, agranulocytosis, alopecia, anaphylactoid reaction, angioedema, ataxia, cerebrovascular accident, chills, coma, confusion, delirium, diabetes mellitus, diabetic ketoacidosis, diabetic coma, difficulty in micturition, DRESS syndrome, dry eye syndrome, dysarthria, facial edema, hangover effect, hepatic injury (cholestatic or mixed), hepatitis, hyperbilirubinemia, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypermenorrhea, hypertriglyceridemia, hypoproteinemia, impotence, increased creatine phosphokinase, intestinal obstruction, jaundice, ketosis, leukocytosis (eosinophilia), leukopenia, liver steatosis, mastalgia, mydriasis, myopathy, nausea, neuroleptic malignant syndrome, neutropenia, osteoporosis, pancreatitis, polyuria, postinjection delirium/sedation syndrome, priapism, pruritus, pulmonary edema, pulmonary embolism, respiratory depression (Cole 2007), restless legs syndrome, rhabdomyolysis, seizure, skin photosensitivity, skin rash, sleep apnea syndrome (obstructive) (Health Canada 2016; Shirani 2011), stupor, suicidal tendencies, syncope, tardive dyskinesia, thrombocytopenia, tongue edema, transient ischemic attacks, urinary frequency, urinary retention, urinary urgency, urticaria, vasodilation, venous thrombosis, withdrawal syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203138\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to olanzapine or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203120\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered cardiac conduction: May alter cardiac conduction; life-threatening arrhythmias have occurred with therapeutic doses of antipsychotics.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems (including narrow-angle glaucoma). Relative to other neuroleptics, olanzapine has a moderate potency of cholinergic blockade (Richelson 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood dyscrasias: Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, preexisting low WBC or history of drug-induced leuko-/neutropenia) should prompt periodic blood count assessment. Discontinue therapy at first signs of blood dyscrasias or if absolute neutrophil count &lt;1,000/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cerebrovascular effects: An increased incidence of cerebrovascular effects (eg, transient ischemic attack, stroke), including fatalities, has been reported in placebo-controlled trials of olanzapine for the unapproved use in elderly patients with dementia-related psychosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which impair physical and mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving). May be moderate to highly sedating in comparison with other antipsychotics (APA [Lehman 2004]); dose-related effects have been observed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dyslipidemia: Dose-related increases in cholesterol and triglycerides have been noted. Use with caution in patients with preexisting abnormal lipid profile.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Esophageal dysmotility/aspiration: Antipsychotic use has been associated with esophageal dysmotility and aspiration; use with caution in patients at risk of pneumonia (ie, Alzheimer disease).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extrapyramidal symptoms: May cause extrapyramidal symptoms (EPS), including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia (risk of these reactions is generally much lower relative to typical/conventional antipsychotics; frequencies reported are similar to placebo). Risk of dystonia (and probably other EPS) may be greater with increased doses, use of conventional antipsychotics, males, and younger patients. Factors associated with greater vulnerability to tardive dyskinesia include older in age, female gender combined with postmenopausal status, Parkinson disease, pseudoparkinsonism symptoms, affective disorders (particularly major depressive disorder), concurrent medical diseases such as diabetes, previous brain damage, alcoholism, poor treatment response, and use of high doses of antipsychotics (APA [Lehman 2004]; Soares-Weiser 2007). Consider therapy discontinuation with signs/symptoms of tardive dyskinesia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Falls: May increase the risk for falls due to somnolence, orthostatic hypotension, and motor or sensory instability. Complete fall risk assessments at baseline and periodically during treatment in patients with diseases or on medications that may also increase fall risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperglycemia: Atypical antipsychotics have been associated with development of hyperglycemia; in some cases, may be extreme and associated with ketoacidosis, hyperosmolar coma, or death. Olanzapine may have a greater association with hyperglycemia than other atypical antipsychotics. Use with caution in patients with diabetes or other disorders of glucose regulation; monitor for worsening of glucose control. Patients with risk factors for diabetes (eg, obesity or family history) should have a baseline fasting blood sugar (FBS) and periodic assessment of glucose regulation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperprolactinemia: May cause dose-related increases in prolactin levels; clinical significance of hyperprolactinemia in patients with breast cancer or other prolactin-dependent tumors is unknown. Clinical manifestations of increased prolactin levels included menstrual-, sexual- and breast-related events.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiorgan hypersensitivity reactions (drug reaction with eosinophilia and systemic symptoms [DRESS]): Potentially serious, sometimes fatal, multiorgan hypersensitivity reactions (DRESS) have been reported. Symptoms may include a cutaneous reaction (rash or exfoliative dermatitis), eosinophilia, fever, and/or lymphadenopathy with systemic complications (eg, hepatitis, nephritis, pneumonitis, myocarditis, pericarditis). Discontinue olanzapine if DRESS is suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuroleptic malignant syndrome (NMS): Use may be associated with NMS; monitor for mental status changes, fever, muscle rigidity, and/or autonomic instability.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use that may predispose to hypotension/bradycardia).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suicidal ideation: The possibility of a suicide attempt is inherent in psychotic illness or bipolar disorder; use with caution in high-risk patients during initiation of therapy. Prescriptions should be written for the smallest quantity consistent with good patient care.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Weight gain: Significant weight gain (&gt;7% of baseline weight) has been observed with antipsychotic therapy; incidence varies with product. Dose-related changes have been observed with olanzapine. Monitor waist circumference and BMI.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with severe cardiac disease, hemodynamic instability, prior myocardial infarction, ischemic heart disease, or hypercholesterolemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dementia: <b>[US Boxed Warning]: Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared with placebo.</b> Most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Use with caution in patients with Lewy body dementia or Parkinson disease dementia due to greater risk of adverse effects, increased sensitivity to extrapyramidal effects, and association with irreversible cognitive decompensation or death. (APA [Reus 2016]). Olanzapine is not approved for the treatment of dementia-related psychosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic disease or impairment; may increase transaminases (primarily ALT).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Parkinson disease: Use with caution in patients with Parkinson disease; antipsychotic may aggravate motor disturbances (APA [Lehman 2004]; APA [Reus 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications that may lower seizure threshold. Elderly patients may be at increased risk of seizures because of an increased prevalence of predisposing factors.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adolescents: Use in patients &ge;13 years of age may result in increased weight gain and sedation, as well as greater increases in LDL cholesterol, total cholesterol, triglycerides, prolactin, and liver transaminase levels when compared with adults. Adolescent patients should be maintained on the lowest dose necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Smokers: Olanzapine levels may be lower in patients who smoke. Smokers may require a daily dose 30% higher than nonsmokers in order to obtain an equivalent olanzapine concentration (Tsuda 2014); however, the manufacturer does not routinely recommend dosage adjustments.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form-specific concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intramuscular formulations: There are two Zyprexa formulations for intramuscular injection: Zyprexa Relprevv is an extended-release formulation and Zyprexa IntraMuscular is short-acting.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Extended-release IM injection (Zyprexa Relprevv):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Postinjection delirium/sedation syndrome: <b>[US Boxed Warning]: Sedation (including coma) and delirium (including agitation, anxiety, confusion, disorientation) have been observed following use of Zyprexa Relprevv;</b> events associated with an inadvertent rapid rise in serum concentrations; administer at a registered health care facility where patients should be continuously monitored (&ge;3 hours) for symptoms of olanzapine overdose; symptom development highest in first hour but may occur within or after 3 hours; risk of syndrome is cumulative with each injection; recovery expected by 72 hours. Upon determining alert status, patient should be escorted to their destination and not drive or operate heavy machinery for the remainder of the day.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Unexplained deaths: Two unexplained deaths in patients who received <i>Zyprexa Relprevv</i> have been reported. The patients died 3 to 4 days after receiving an appropriate dose of the drug. Both patients were found to have high blood concentrations of olanzapine postmortem. It is unclear if these deaths were the result of postinjection delirium sedation syndrome (PDSS) (FDA Safety Communication 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Restricted distribution program: Zyprexa Relprevv is only available under a restricted distribution program. Only prescribers, health care facilities, and pharmacies registered with the program are able to prescribe, distribute, or dispense Zyprexa Relprevv for patients who are enrolled in and meet all conditions of the program.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Short-acting IM injection (Zyprexa IntraMuscular):</i> Patients should remain recumbent if drowsy/dizzy until hypotension, bradycardia, and/or hypoventilation have been ruled out. Closely monitor for orthostasis prior to any repeat dosing. Concurrent use of IM/IV benzodiazepines is not recommended (fatalities have been reported, though causality not determined).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>\n          <b>Other warnings/precautions</b>:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: When discontinuing antipsychotic therapy, the American Psychiatric Association (APA), Canadian Psychiatric Association (CPA), and World Federation of Societies of Biological Psychiatry (WFSBP) guidelines recommend gradually tapering antipsychotics to avoid physical withdrawal symptoms, including anorexia, anxiety, diaphoresis, diarrhea, dizziness, dyskinesia, headache, myalgia, nausea, paresthesia, restlessness, tremulousness, and vomiting (APA [Lehman 2004]; CPA [Addington 2005]; Lambert 2007; WFSBP [Hasan 2012]). The risk of withdrawal symptoms is highest following abrupt discontinuation of highly anti-cholinergic or dopaminergic antipsychotics (Cerovecki 2013). Additional factors such as duration of antipsychotic exposure, the indication for use, medication half-life, and risk for relapse should be considered. In schizophrenia, there is no reliable indicator to differentiate the minority who will not from the majority who will relapse with drug discontinuation. However, studies in which the medication of well-stabilized patients were discontinued indicate that 75% of patients relapse within 6 to 24 months. Indefinite maintenance antipsychotic medication is generally recommended, and especially for patients who have had multiple prior episodes or 2 episodes within 5 years (APA [Lehman 2004]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; IV administration: IV administration has only been studied in emergency department settings, where patients can be closely monitored for respiratory depression (ie, pulse oximetry) (Chan 2013; Cole 2017; Martel 2015; Taylor 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203191\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (major), CYP2D6 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203125\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9716&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May diminish the anticholinergic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Amifampridine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amisulpride: Antipsychotic Agents may enhance the adverse/toxic effect of Amisulpride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: Antipsychotic Agents may diminish the stimulatory effect of Amphetamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihepaciviral Combination Products: May decrease the serum concentration of OLANZapine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anti-Parkinson Agents (Dopamine Agonist): Antipsychotic Agents (Second Generation [Atypical]) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).  Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzodiazepines: OLANZapine may enhance the adverse/toxic effect of Benzodiazepines.  Management: Avoid concomitant use of parenteral benzodiazepines and IM olanzapine due to risks of additive adverse events (e.g., cardiorespiratory depression). Olanzapine prescribing information provides no specific recommendations regarding oral administration.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of OLANZapine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inducers (Moderate): May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyproterone: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FluvoxaMINE: May increase the serum concentration of OLANZapine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: Antipsychotic Agents may diminish the therapeutic effect of Guanethidine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LamoTRIgine: May enhance the sedative effect of OLANZapine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: May enhance the neurotoxic effect of Antipsychotic Agents. Lithium may decrease the serum concentration of Antipsychotic Agents. Specifically noted with chlorpromazine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mequitazine: Antipsychotic Agents may enhance the arrhythmogenic effect of Mequitazine.  Management: Consider alternatives to one of these agents when possible.  While this combination is not specifically contraindicated, mequitazine labeling describes this combination as discouraged.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: Antipsychotic Agents may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obeticholic Acid: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: Antipsychotic Agents may diminish the therapeutic effect of Piribedil. Piribedil may diminish the therapeutic effect of Antipsychotic Agents.  Management: Use of piribedil with antiemetic neuroleptics is contraindicated, and use with antipsychotic neuroleptics, except for clozapine, is not recommended.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Moderate Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: Antipsychotic Agents may diminish the therapeutic effect of Quinagolide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May decrease the serum concentration of OLANZapine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<b> Exceptions: </b>Nicergoline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulpiride: Antipsychotic Agents may enhance the adverse/toxic effect of Sulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: May decrease the serum concentration of OLANZapine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203127\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2839122\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events were observed in animal reproduction studies. Olanzapine crosses the placenta and can be detected in cord blood at birth (Newport 2007). Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and/or withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The ACOG recommends that therapy during pregnancy be individualized; treatment with psychiatric medications during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary health care provider, and pediatrician. Safety data related to atypical antipsychotics during pregnancy is limited, as such, routine use is not recommended. However, if a woman is inadvertently exposed to an atypical antipsychotic while pregnant, continuing therapy may be preferable to switching to an agent that the fetus has not yet been exposed to; consider risk:benefit (ACOG 2008). If treatment is needed in a woman planning a pregnancy or if treatment is initiated during pregnancy, olanzapine may be used (Larsen 2015).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Olanzapine may cause hyperprolactinemia, which may decrease reproductive function in both males and females.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Health care providers are encouraged to enroll women 18 to 45 years of age exposed to olanzapine during pregnancy in the Atypical Antipsychotics Pregnancy Registry (1-866-961-2388 or http://www.womensmentalhealth.org/pregnancyregistry).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2839124\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Olanzapine is present in breast milk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The relative infant dose (RID) of olanzapine is 1.7% when calculated using the highest breast milk concentration located and compared to a weight-adjusted maternal dose of 286 mcg/kg/day.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000). Some sources note breastfeeding should only be considered if the RID is &lt;5% for psychotropic agents (Larsen 2015).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The RID of olanzapine was calculated using a milk concentration of 0.033 mcg/mL, providing an estimated daily infant dose via breast milk of 4.95 mcg/kg/day. This milk concentration was obtained following maternal administration of olanzapine 286 mcg/kg/day. This paper also presented breast milk concentrations from additional mother infant pairs. Using data from six women, the mean maximum milk concentration appeared 5.2 hours after the maternal dose and the mean RID was 1.02% (range: 0.93% to 1.12%). Women in the study received oral olanzapine 5 to 20 mg/day (mean: 7.5 mg/day), were taking the medication for 19 to 395 days before sampling (considered to be at steady state), and infants were between 0.1 to 4.3 months of age (Gardiner 2003). Olanzapine has been detected in the serum of a breastfeeding infant; concentrations were highest when first measured at 4 months of age and decreased over time, possibly due to CYP metabolism which matures as the child ages. Maternal doses varied based on maternal symptoms, but ranged from 5 to 15 mg/day (Whitworth 2010).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In the majority of cases, adverse events have not been noted in breastfeeding infants; when observed, insomnia, irritability, somnolence, and tremor were the most common adverse events reported to the manufacturer (Brunner 2013). In general, infants exposed to second generation antipsychotics via breast milk should be monitored weekly for the first month of exposure for symptoms such as appetite changes, insomnia, irritability, or lethargy (Uguz 2016). Although breastfeeding is not recommended by the manufacturer, when an antipsychotic medication is needed in a breastfeeding woman, olanzapine is preferred (Larsen 2015; Pacchiaarotti 2016; Uguz 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203141\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Tablets may be taken without regard to meals. Some products may contain phenylalanine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203129\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Mental status; vital signs (as clinically indicated); blood pressure (baseline; repeat 3 months after antipsychotic initiation, then yearly); weight, height, BMI, waist circumference (baseline; repeat at 4, 8, and 12 weeks after initiating or changing therapy, then quarterly; consider switching to a different antipsychotic for a weight gain &ge;5% of initial weight); CBC (as clinically indicated; monitor frequently during the first few months of therapy in patients with pre-existing low WBC or history of drug-induced leukopenia/neutropenia); electrolytes and liver function (annually and as clinically indicated); personal and family history of obesity, diabetes, dyslipidemia, hypertension, or cardiovascular disease (baseline; repeat annually); fasting plasma glucose level/HbA<sub>1c</sub> (baseline; repeat 3 months after starting antipsychotic, then yearly); fasting lipid panel (baseline; repeat 3 months after initiation of antipsychotic; if LDL level is normal repeat at 2-5 year intervals or more frequently if clinical indicated); changes in menstruation, libido, development of galactorrhea, erectile and ejaculatory function (at each visit for the first 12 weeks after the antipsychotic is initiated or until the dose is stable, then yearly); abnormal involuntary movements or parkinsonian signs (baseline; repeat weekly until dose stabilized for at least 2 weeks after introduction and for 2 weeks after any significant dose increase); tardive dyskinesia (every 12 months; high-risk patients every 6 months); ocular examination (yearly in patients &gt;40 years; every 2 years in younger patients) (ADA 2004; Lehman 2004; Marder 2004)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Extended-release IM injection: Sedation/delirium for 3 hours after each dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203119\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Olanzapine is a second generation thienobenzodiazepine antipsychotic which displays potent antagonism of serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub>, dopamine D<sub>1-4</sub>, histamine H<sub>1</sub>, and alpha<sub>1</sub>-adrenergic receptors. Olanzapine shows moderate antagonism of 5-HT<sub>3</sub> and  muscarinic M<sub>1-5 </sub>receptors, and weak binding to GABA-A, BZD, and beta-adrenergic receptors. Although the precise mechanism of action in schizophrenia and bipolar disorder is not known, the efficacy of olanzapine is thought to be mediated through combined antagonism of dopamine and serotonin type 2 receptor sites. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203137\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Within 1 to 2 weeks for control of aggression, agitation, insomnia; 3 to 6 weeks for control of mania and positive psychotic symptoms. Adequate trial: Typically 6 weeks at maximum tolerated doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Well absorbed; not affected by food; tablets and orally disintegrating tablets are bioequivalent</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Short-acting injection: Rapidly absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: Extensive, 1,000 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding, plasma: 93% bound to albumin and alpha<sub>1</sub>-glycoprotein</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Highly metabolized via direct glucuronidation and cytochrome P450 mediated oxidation (CYP1A2, CYP2D6); 40% removed via first pass metabolism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral and IM (short-acting): Children: (10 to 18 years; n=8): 37.2 &plusmn; 5.1 hours (Grothe 2000); Adults: 30 hours [21 to 54 hours (5th to 95th percentile)]; approximately 1.5 times greater in elderly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Extended-release injection: ~30 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: Maximum plasma concentrations after IM administration are 5 times higher than maximum plasma concentrations produced by an oral dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Extended-release injection: ~7 day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Short-acting injection: 15 to 45 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: Children (10 to 18 years; n=8): 4.7 &plusmn; 3.7 hours (Grothe 2000); Adults: ~6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (57%, 7% as unchanged drug); feces (30%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clearance: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children (10 to 18 years; n=8): Apparent: 9.6 &plusmn; 2.4 L/hour (Grothe 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: Apparent: 25 L/hour [12 to 47 L/hour (5th to 95th percentile)]; 40% increase in olanzapine clearance in smokers; 30% decrease in females</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203140\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (OLANZapine Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (1): $41.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (ZyPREXA Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (1): $51.52</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (ZyPREXA Relprevv Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">210 mg (1): $707.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (1): $1,010.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">405 mg (1): $1,364.69</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, orally-disintegrating</b> (OLANZapine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (30): $428.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $629.17</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (30): $927.85</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (30): $1,226.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, orally-disintegrating</b> (ZyPREXA Zydis Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (1): $17.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (1): $25.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (1): $37.67</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (1): $49.82</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (OLANZapine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (30): $335.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (30): $396.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mg (30): $481.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $596.79</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (30): $895.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (30): $1,193.58</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (ZyPREXA Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (30): $410.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (30): $484.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mg (30): $589.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $729.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (30): $1,094.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (30): $1,459.44</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203142\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aedon (AT, CZ);</li>\n      <li>Arenbil (ES);</li>\n      <li>Benexafrina OD (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Benzopain (JO);</li>\n      <li>Dozic (CO, PY);</li>\n      <li>Egolanza (CZ, VN);</li>\n      <li>Exzapine (PH);</li>\n      <li>Lanzine (TZ);</li>\n      <li>Lapozan (LV);</li>\n      <li>Lopez (BD);</li>\n      <li>Marathon (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Meflax (EC);</li>\n      <li>Midax (PY);</li>\n      <li>Nodoff (TW);</li>\n      <li>Nykob (CZ);</li>\n      <li>Okpine (TW);</li>\n      <li>Olan (LK);</li>\n      <li>Olandoz (ID);</li>\n      <li>Olankline (MY, SG);</li>\n      <li>Olanpin (KR);</li>\n      <li>Olanstad (VN);</li>\n      <li>Olanza (BD, HK, PH, TH);</li>\n      <li>Olanza OD (KR);</li>\n      <li>Olanzapro (PH);</li>\n      <li>Olapin-10 (KR, TH);</li>\n      <li>Olapine (BD);</li>\n      <li>Olazax (AT, IE);</li>\n      <li>Olazine (QA);</li>\n      <li>Oleanz (IN);</li>\n      <li>Olmed (VN);</li>\n      <li>Onzapin (HK, ID, SG);</li>\n      <li>Onzapin OD (HK);</li>\n      <li>Onzapin ODT (SG);</li>\n      <li>Ozapex (KR);</li>\n      <li>Ozin (AU);</li>\n      <li>Placet (PY, UY);</li>\n      <li>Prexal (JO, QA);</li>\n      <li>Remital (ID);</li>\n      <li>Rolyprexa (IE);</li>\n      <li>Tiantrex (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Tolanz (LK);</li>\n      <li>Tolaz MD (IN);</li>\n      <li>Torolan (VN);</li>\n      <li>Ximin (CN);</li>\n      <li>Xytrex (BD);</li>\n      <li>Zalasta (ES, IE, LV, MT, PL, UA);</li>\n      <li>Zanprex (PH);</li>\n      <li>Zapilux (BG);</li>\n      <li>Zapine (LK);</li>\n      <li>Zappa (IL);</li>\n      <li>Zelta (CO, CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Zeprex (PH);</li>\n      <li>Zolafren (ES, VN);</li>\n      <li>Zozapin (LK);</li>\n      <li>Zylap (AU);</li>\n      <li>Zypadhera (AT, DE, DK, EE, ES, FR, GB, HR, IE, IL, IS, LT, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR);</li>\n      <li>ZypAdhera (QA);</li>\n      <li>Zypeace OD (KR);</li>\n      <li>Zypine (AU);</li>\n      <li>Zypine ODT (AU);</li>\n      <li>Zypreksa (UA);</li>\n      <li>Zyprexa (AE, AR, AT, AU, BB, BE, BF, BH, BJ, BR, CH, CI, CL, CN, CO, CY, CZ, DE, DK, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, HK, HR, ID, IE, IL, IS, IT, JO, JP, KE, KW, LB, LR, LT, LU, LV, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, NZ, PE, PH, PK, PL, PT, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, TH, TN, TR, TW, TZ, UG, VE, VN, ZA, ZM, ZW);</li>\n      <li>Zyprexa Velotab (AE, AT, BE, BG, CH, CY, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, KW, LB, MT, NL, NO, PL, PT, QA, RU, SE, SK, TR);</li>\n      <li>Zyprexa Zydis (AR, BB, CN, HK, ID, MY, NZ, PH, SG, TH, TW);</li>\n      <li>Zyrepin (KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins-Obstetrics, &quot;ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 92, April 2008 (Replaces Practice Bulletin Number 87, November 2007). Use of Psychiatric Medications During Pregnancy and Lactation,&quot; <i>Obstet Gynecol</i>, 2008, 111(4):1001-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/18378767/pubmed\" target=\"_blank\" id=\"18378767\">18378767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. <i>J Clin Psychiatry</i>. 2004;65(2):267-272.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/15003083/pubmed\" target=\"_blank\" id=\"15003083\">15003083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span><span class=\"doi\">10.1111/jgs.13702</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB, Lane JR, et al, &ldquo;Hydrocodone Excretion Into Breast Milk: The First Two Reported Cases,&rdquo; <i>Breastfeed Med</i>, 2007, 2(1):10-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/17661614/pubmed\" target=\"_blank\" id=\"17661614\">17661614</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baldwin DS and Montgomery SA, &ldquo;First Clinical Experience With Olanzapine (LY 170053): Results of an Open-Label Safety and Dose-Ranging Study in Patients With Schizophrenia,&rdquo; <i>Int Clin Psychopharmacol</i>, 1995, 10(4):239-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/8748045/pubmed\" target=\"_blank\" id=\"8748045\">8748045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: american society of clinical oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2011;29(31):4189-4198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/22379425/pubmed\" target=\"_blank\" id=\"22379425\">22379425</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18484558\"></a>Bosmans A, Verbanck P. Successful treatment of delusional disorder of the somatic type or &quot;delusional parasitosis&quot; with olanzapine. <i>Pharmacopsychiatry.</i> 2008;41(3):121-122.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/18484558/pubmed\" target=\"_blank\" id=\"18484558\">18484558</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23902726\"></a>Brunner E, Falk DM, Jones M, Dey DK, Shatapathy CC. Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance. <i>BMC Pharmacol Toxicol</i>. 2013;14:38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/23902726/pubmed\" target=\"_blank\" id=\"23902726\">23902726</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11379844\"></a>Budman CL, Gayer A, Lesser M, Shi Q, Bruun RD. An open-label study of the treatment efficacy of olanzapine for Tourette's disorder. J Clin Psychiatry. 2001;62(4):290-294.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/11379844/pubmed\" target=\"_blank\" id=\"11379844\">11379844</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Canadian Psychiatric Association. Clinical practice guidelines. Treatment of schizophrenia. <i>Can J Psychiatry</i>. 2005;50(13)(suppl 1):7S-57S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/16529334/pubmed\" target=\"_blank\" id=\"16529334\">16529334</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22730105\"></a>Carey P, Suliman S, Ganesan K, Seedat S, Stein DJ. Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study. <i>Hum Psychopharmacol</i>. 2012;27(4):386-391.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/22730105/pubmed\" target=\"_blank\" id=\"22730105\">22730105</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carrillo JA, Herraiz AG, Ramos SI, et al, &ldquo;Role of the Smoking-Induced Cytochrome P450 (CYP)1A2 and Polymorphic CYP2D6 in Steady-State Concentration of Olanzapine,&rdquo; <i>J Clin Psychopharmacol</i>, 2003, 23(2):119-27.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cerovecki A, Musil R, Klimke A, et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. <i>CNS Drugs</i>. 2013;27(7):545-572. doi: 10.1007/s40263-013-0079-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/23821039/pubmed\" target=\"_blank\" id=\"23821039\">23821039</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chan EW, Taylor DM, Knott JC, et al. Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double-blind, placebo-controlled clinical trial. <i>Ann Emerg Med.</i> 2013;61(1):72-81. doi: 10.1016/j.annemergmed.2012.07.118.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/22981685/pubmed\" target=\"_blank\" id=\"22981685\">22981685</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cole JB, Moore JC, Dolan BJ, et al. A prospective observational study of patients receiving intravenous and intramuscular olanzapine in the emergency department. <i>Ann Emerg Med.</i> 2017;69(3):327-336. doi: 10.1016/j.annemergmed.2016.08.008.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/27823873/pubmed\" target=\"_blank\" id=\"27823873\">27823873</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davis JM, Chen N, and Glick ID, &ldquo;A Meta-analysis of the Efficacy of Second-Generation Antipsychotics,&rdquo; <i>Arch Gen Psychiatry</i>, 2003, 60(6):553-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/12796218/pubmed\" target=\"_blank\" id=\"12796218\">12796218</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14758577\"></a>De Deyn PP, Carrasco MM, Deberdt W, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. <i>Int J Geriatr Psychiatry</i>. 2004;19(2):115-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/14758577/pubmed\" target=\"_blank\" id=\"14758577\">14758577</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dixon L, Perkins D, and Calmes C, <i>Guideline Watch (September 2009): Practice Guideline for the Treatment of Schizophrenia</i>, Arlington, Va: American Psychiatric Association, 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Duggal HS, Gates C, and Pathak PC, &ldquo;Olanzapine-Induced Neutropenia: Mechanism and Treatment,&rdquo; <i>J Clin Psychopharmacol</i>, 2004, 24(2):234-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/15206675/pubmed\" target=\"_blank\" id=\"15206675\">15206675</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Farwell WR, Stump TE, Wang J, et al, &ldquo;Weight Gain and New Onset Diabetes Associated With Olanzapine and Risperidone,&rdquo; <i>J Gen Intern Med</i>, 2004, 19(12):1200-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/15610330/pubmed\" target=\"_blank\" id=\"15610330\">15610330</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    FDA MedWatch Safety Information and Adverse Event Reporting Program. Zyprexa Relprevv (olanzapine pamoate): Drug Safety Communication - FDA investigating two deaths following injection. <a href=\"http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm357601.htm\" target=\"_blank\">http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm357601.htm</a>. Published June 18, 2013. Accessed May 22, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flank J, Robinson PD, Holdsworth M, et al. Guideline for the treatment of breakthrough and the prevention of refractory chemotherapy-induced nausea and vomiting in children with cancer. <i>Pediatr Blood Cancer</i>. 2016;63(7):1144-1451.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/26960036/pubmed\" target=\"_blank\" id=\"26960036\">26960036</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18794644\"></a>Freudenmann RW, Lepping P. Second-generation antipsychotics in primary and secondary delusional parasitosis: outcome and efficacy. <i>J Clin Psychopharmacol.</i> 2008;28(5):500-508.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/18794644 /pubmed\" target=\"_blank\" id=\"18794644 \">18794644 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gardiner SJ, Kristensen JH, Begg EJ, et al, &quot;Transfer of Olanzapine Into Breast Milk, Calculation of Infant Drug Dose, and Effect on Breast-Fed Infants,&quot; <i>Am J Psychiatry</i>, 2003, 160(8):1428-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/12900304/pubmed\" target=\"_blank\" id=\"12900304\">12900304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garriga M, Pacchiarotti I, Kasper S, et al. World Federation of Societies of Biological Psychiatry. Assessment and management of agitation in psychiatry: expert consensus. World J Biol Psychiatry. 2016;17(2):86-128. doi: 10.3109/15622975.2015.1132007.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/26912127/pubmed\" target=\"_blank\" id=\"26912127\">26912127</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gilad O, Merlob P, Stahl B, et al, &quot;Outcome of Infants Exposed to Olanzapine During Breastfeeding,&quot; <i>Breastfeed Med</i>, 2011, 6(2):55-8<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/21034242/pubmed\" target=\"_blank\" id=\"21034242\">21034242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gill SS, Bronskill SE, Normand SL, et al, &ldquo;Antipsychotic Drug Use and Mortality in Older Adults With Dementia,&rdquo; <i>Ann Intern Med</i>, 2007, 146(11):775-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/17548409/pubmed\" target=\"_blank\" id=\"17548409\">17548409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldberg RJ, &ldquo;Managing Psychosis-Related Behavioral Problems in the Elderly,&rdquo; <i>Consult Pharm</i>, 1997, 12(Suppl C):4-10.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldstein DJ, Corbin LA, and Fung MC, &quot;Olanzapine-Exposed Pregnancies and Lactation: Early Experience,&quot; <i>J Clin Psychopharmacol</i>, 2000, 20(4):399-403.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/10917399/pubmed\" target=\"_blank\" id=\"10917399\">10917399</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gorski ED and Willis KC, &ldquo;Report of Three Cases Studied With Olanzapine for Chronic Pain,&rdquo; <i>J Pain</i>, 2003, 4:166-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/14622714/pubmed\" target=\"_blank\" id=\"14622714\">14622714</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grothe DR, Calis KA, Jacobsen L, et al, &quot;Olanzapine Pharmacokinetics in Pediatric and Adolescent Inpatients With Childhood-Onset Schizophrenia,&quot; <i>J Clin Psychopharmacol</i>, 2000, 20(2):220-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/10770461/pubmed\" target=\"_blank\" id=\"10770461\">10770461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hasan A, Falkai P, Wobrock T, et al; World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. <i>World J Biol Psychiatry</i>. 2012;13(5):318-378. doi: 10.3109/15622975.2012.696143.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/22834451/pubmed\" target=\"_blank\" id=\"22834451\">22834451</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Healthy Canadians Recalls &amp; Alerts: Summary Safety Review - Atypical antipsychotics - assessing the potential risk of sleep apnoea. Health Canada website. Available at: http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/antipsycho2-eng.php. Published August 16, 2016. Accessed August 23, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heller MM, Wong JW, Lee ES, et al. Delusional infestations: clinical presentation, diagnosis and treatment. <i>Int J Dermatol.</i> 2013;52(7):775-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/23789596/pubmed\" target=\"_blank\" id=\"23789596\">23789596</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20465623\"></a>Kenchaiah BK, Kumar S, Tharyan P. Atypical anti-psychotics in delusional parasitosis: a retrospective case series of 20 patients. <i>Int J Dermatol. </i>2010;49(1):95-100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/20465623/pubmed\" target=\"_blank\" id=\"20465623\">20465623</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khojainova N, Santiago-Palma J, Kornick C, et al, &ldquo;Olanzapine in the Management of Cancer Pain,&rdquo; <i>J Pain Symptom Manage</i>, 2002, 23(4):346-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/11997204/pubmed\" target=\"_blank\" id=\"11997204\">11997204</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kiser RS, Cohen HM, Freedenfeld RN, et al, &ldquo;Olanzapine for the Treatment of Fibromyalgia Symptoms,&rdquo; <i>J Pain Symptom Manage</i>, 2001, 22(2):704-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/11495717/pubmed\" target=\"_blank\" id=\"11495717\">11495717</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kroon LA, &ldquo;Drug Interactions With Smoking,&rdquo; <i>Am J Health Syst Pharm</i>, 2007, 64(18):1917-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/17823102/pubmed\" target=\"_blank\" id=\"17823102\">17823102</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kryzhanovskaya L, Schulz SC, McDougle C, et al, &ldquo;Olanzapine Versus Placebo in Adolescents With Schizophrenia: A 6-Week, Randomized, Double-Blind, Placebo-Controlled Trial,&rdquo; <i>J Am Acad Child Adolesc Psychiatr</i>y, 2009, 48(1):60-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/19057413/pubmed\" target=\"_blank\" id=\"19057413\">19057413</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kumra S, Jacobsen LK, Lenane M et al, &ldquo;Childhood-Onset Schizophrenia: An Open-Label Study of Olanzapine in Adolescents,&rdquo; <i>J Am Acad Child Adolesc Psychiatry</i>, 1998, 37(4):377-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/9549958/pubmed\" target=\"_blank\" id=\"9549958\">9549958</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. <i>J Clin Psychiatry</i>. 2007;68(suppl 6):10-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/17650054/pubmed\" target=\"_blank\" id=\"17650054\">17650054</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/26344706/pubmed\" target=\"_blank\" id=\"26344706\">26344706</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lauriello J, Lambert T, Andersen S, et al, &ldquo;An 8-Week, Double-Blind, Randomized, Placebo-Controlled Study of Olanzapine Long-Acting Injection in Acutely Ill Patients With Schizphrenia,&rdquo; <i>J Clin Psychiatry</i>, 2008, 69(5):790-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/18452346/pubmed\" target=\"_blank\" id=\"18452346\">18452346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lehman AF, Lieberman JA, Dixon LB, et al, American Psychiatric Association, Steering Committee on Practice Guidelines. Practice guidelines for the treatment of patients with schizophrenia, second edition. <i>Am J Psychiatry</i>. 2004;161(2 Suppl):1-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/15000267/pubmed\" target=\"_blank\" id=\"15000267\">15000267</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17172913\"></a>Lim GC, Chen YF, Liu L, Huang SC, Lin KK, Hsiao CH. Camphor-related self-inflicted keratoconjunctivitis complicating delusions of parasitosis. <i>Cornea.</i> 2006;25(10):1254-1256.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/17172913/pubmed\" target=\"_blank\" id=\"17172913\">17172913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. <i>Am J Psychiatry</i>. 2004;161(8):1334-1349.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/15285957/pubmed\" target=\"_blank\" id=\"15285957\">15285957</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martel ML, Klein LR, Rivard RL, et al. A large retrospective cohort of patients receiving intravenous olanzapine in the emergency department.<i> Acad Emerg Med.</i> 2016;23(1):29-35. doi: 10.1111/acem.12842.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/26720055/pubmed\" target=\"_blank\" id=\"26720055\">26720055</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18928414\"></a>McCracken JT, Suddath R, Chang S, Thakur S, Piacentini J. Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome. <i>J Child Adolesc Psychopharmacol</i>. 2008;18:501-508.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/18928414/pubmed\" target=\"_blank\" id=\"18928414\">18928414</a>]</span><span class=\"doi\">10.1089/cap.2007.135</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11927174\"></a>Meehan KM, Wang H, David SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. <i>Neuropsychopharmacology</i>. 2002;26(4):494-504.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/11927174/pubmed\" target=\"_blank\" id=\"11927174\">11927174</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22689836\"></a>Meraj A, Din AU, Larsen L, Liskow BI. Self inflicted corneal abrasions due to delusional parasitosis. <i>BMJ Case Rep.</i> 2011;2011.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/22689836 /pubmed\" target=\"_blank\" id=\"22689836 \">22689836 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moore TA, &ldquo;Schizophrenia Treatment Guidelines in the United States,&rdquo; <i>Clin Schizophr Relat Psychoses</i>, 2011, 5(1):40-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/21459738/pubmed\" target=\"_blank\" id=\"21459738\">21459738</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Multinational Association of Supportive Care in Cancer. MASCC/ESMO antiemetic guideline 2016. http://www.mascc.org/assets/Guidelines-Tools/mascc_antiemetic_guidelines_english_2016_v.1.1.pdf. Accessed June 15, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murphy TK, Lewin AB, Storch EA, Stock S; American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with tic disorders. <i>J Am Acad Child Adolesc Psychiatry</i>. 2013;52(12):1341-1359.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/24290467/pubmed\" target=\"_blank\" id=\"24290467\">24290467</a>]</span><span class=\"doi\">10.1016/j.jaac.2013.09.015</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Institute for Health and Clinical Excellence (NICE), National Clinical Guideline Centre, &ldquo;Delirium: Diagnosis, Prevention and Management,&rdquo; National Clinical Practice Guideline Number 103, 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Navari RM and Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. <i>N Engl J Med</i>. 2016;374(14):1356-1367.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/27050207/pubmed\" target=\"_blank\" id=\"27050207\">27050207</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17375339\"></a>Navari RM, Einhorn LH, Loehrer PJ, et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a hoosier oncology group study. <i>Support Care Cancer</i>, 2007, 15(11):1285-1291.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/17375339/pubmed\" target=\"_blank\" id=\"17375339\">17375339</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22024310\"></a>Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. <i>J Support Oncol</i>. 2011;9(5):188-195.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/22024310/pubmed\" target=\"_blank\" id=\"22024310\">22024310</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23314603\"></a>Navari RM, Nagy CK, Gray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. <i>Support Care Cancer.</i> 2013;21(6):1655-1663.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/23314603/pubmed\" target=\"_blank\" id=\"23314603\">23314603</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Newport DJ, Calamaras MR, DeVane CL, et al, &quot;Atypical Antipsychotic Administration During Late Pregnancy: Placental Passage and Obstetrical Outcomes,&quot; <i>Am J Psychiatry</i>, 2007, 164(8):1214-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/17671284/pubmed\" target=\"_blank\" id=\"17671284\">17671284</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10929273\"></a>Onofrj M, Paci C, D'Andreamatteo G, Toma L. Olanzapine in severe Gilles de la Tourette syndrome: a 52-week double-blind cross-over study vs. low-dose pimozide. <i>J Neurol</i>. 2000;247(6):443-446.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/10929273/pubmed\" target=\"_blank\" id=\"10929273\">10929273</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pacchiarotti I, Le&oacute;n-Caballero J, Murru A, et al. Mood stabilizers and antipsychotics during breastfeeding: Focus on bipolar disorder. <i>Eur Neuropsychopharmacol</i>. 2016;26(10):1562-1578.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/27568278/pubmed\" target=\"_blank\" id=\"27568278\">27568278</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Passick SD, Navari RM, Jung SH, et al, &ldquo;A Phase I Trial of Olanzapine (Zyprexa) for the Prevention of Delayed Emesis in Cancer Patients: A Hoosier Oncology Group Study,&rdquo; <i>Cancer Invest</i>, 2004, 22(3):383-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/15493359/pubmed\" target=\"_blank\" id=\"15493359\">15493359</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pringsheim T, Doja A, Gorman D, et al. Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. <i>Can J Psychiatry</i>. 2012;57(3):133-143. Review.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/22397999/pubmed\" target=\"_blank\" id=\"22397999\">22397999</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Remington G, Chue P, Stip E, Kopala L, Girard T, Christensen B. The crossover approach to switching antipsychotics: what is the evidence? <i>Schizophr Res</i>. 2005;76(2-3):267-272. doi: 10.1016/j.schres.2005.01.009.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/15949658/pubmed\" target=\"_blank\" id=\"15949658\">15949658</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016;173(5):543-546. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.2015.173501. Accessed May 26, 2016. doi: 10.1176/appi.ajp.2015.173501.27133416</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. <i>J Clin Psychiatry</i>. 1999;60 suppl 10:5-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/10340682/pubmed\" target=\"_blank\" id=\"10340682\">10340682</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roessner V, Plessen KJ, Rothenberger A, et al. ESSTS Guidelines Group. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. <i>Eur Child Adolesc Psychiatry</i>. 2011;20(4):173-196.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/21445724/pubmed\" target=\"_blank\" id=\"21445724\">21445724</a>]</span><span class=\"doi\">10.1007/s00787-011-0163-7</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rozen TD, &ldquo;New Treatments in Cluster Headache,&rdquo; <i>Curr Neurol Neurosci Rep</i>, 2002, 2(2):114-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/11898477/pubmed\" target=\"_blank\" id=\"11898477\">11898477</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schneeweiss S, Setoguchi S, Brookhart A, et al, &ldquo;Risk of Death Associated With the Use of Conventional Versus Atypical Antipsychotic Drugs Among Elderly Patients,&rdquo; <i>CMAJ</i>, 2007, 176(5): 627-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/17325327/pubmed\" target=\"_blank\" id=\"17325327\">17325327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17035647\"></a>Schneider LS, Tariot PN, Dagerman KS, et al; CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. <i>N Engl J Med</i>. 2006;355:1525-1538.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/17035647/pubmed\" target=\"_blank\" id=\"17035647\">17035647</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shaw P, Sporn A, Gogtay N et al, &ldquo;Childhood-Onset Schizophrenia: A Double-Blind, Randomized Clozapine-Olanzapine Comparison,&rdquo; <i>Arch Gen Psychiatry</i>, 2006, 63(7):721-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/16818861/pubmed\" target=\"_blank\" id=\"16818861\">16818861</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shirani A, Paradiso S, Dyken ME. The impact of atypical antipsychotic use on obstructive sleep apnea: a pilot study and literature review. <i>Sleep Med</i>. 2011;12(6):591-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/21645873/pubmed\" target=\"_blank\" id=\"21645873\">21645873</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Soares-Weiser K, Fernandez HH. Tardive dyskinesia. <i>Semin Neurol</i>. 2007;27(2):159-169.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/17390261/pubmed\" target=\"_blank\" id=\"17390261\">17390261</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sorsaburu S, Hornbuckle K, Blake D, et al, &ldquo;The First 21 Months of Safety Experience With Postmarketing Use of Olanzapine's Intramuscular Formulation,&rdquo; College of Psychiatric and Neurologic Pharmacists, April, 2006, Baltimore, MD.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Soutullo CA, Sorter MT, Foster KD, et al, &ldquo;Olanzapine in the Treatment of Adolescent Acute Mania: A Report of Seven Cases,&rdquo; <i>J Affect Disord</i>, 1999, 53(3):279-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/10404715/pubmed\" target=\"_blank\" id=\"10404715\">10404715</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10836282\"></a>Stamenkovic M, Schindler SD, Aschauer HN, et al. Effective open-label treatment of tourette's disorder with olanzapine. <i>Int Clin Psychopharmacol</i>. 2000;15:23-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/10836282/pubmed\" target=\"_blank\" id=\"10836282\">10836282</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12359687\"></a>Stein MB, Kline NA, Matloff JL. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. <i>Am J Psychiatry</i>. 2002;159(10):1777-1779.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/12359687/pubmed\" target=\"_blank\" id=\"12359687\">12359687</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11015815\"></a>Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. <i>Arch Gen Psychiatry</i>. 2000;57(10):968-976.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/11015815/pubmed\" target=\"_blank\" id=\"11015815\">11015815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Street JS, Clark WS, Kadam DL, et al. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia. <i>Int J Geriatr Psychiatry</i>. 2001;16 Suppl 1:S62-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/11748789/pubmed\" target=\"_blank\" id=\"11748789\">11748789</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15319022\"></a>Stephens RJ, Bassel C, Sandor P. Olanzapine in the treatment of aggression and tics in children with Tourette's syndrome--a pilot study. <i>J Child Adolesc Psychopharmacol</i>. 2004;14(2):255-266.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/15319022/pubmed\" target=\"_blank\" id=\"15319022\">15319022</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18519523\"></a>Sultzer DL, Davis SM, Tariot PN, et al; CATIE-AD Study Group. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. <i>Am J Psychiatry</i>. 2008;165(7):844-854.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/18519523/pubmed\" target=\"_blank\" id=\"18519523\">18519523</a>]</span><span class=\"doi\">10.1176/appi.ajp.2008.07111779</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Suppes T, Dennehy EB, Hirschfeld RMA, et al, &ldquo;The Texas Implementation of Medication Algorithms: Update to the Algorithms for the Treatment of Bipolar I Disorder,&rdquo; <i>J Clin Psychiatry</i>, 2005, 66(7):870-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/16013903/pubmed\" target=\"_blank\" id=\"16013903\">16013903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taylor DM, Yap CY, Knott JC, et al. Midazolam-droperidol, droperidol, or olanzapine for acute agitation: a randomized clinical trial.<i> Ann Emerg Med.</i> 2017;69(3):318-326. doi: 10.1016/j.annemergmed.2016.07.033.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/27745766/pubmed\" target=\"_blank\" id=\"27745766\">27745766</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thangadurai P, Jyothi KS, Gopalakrishman R, et al, &ldquo;Reversible Neutropenia With Olanzapine Following Clozapine-Induced Neutropenia,&rdquo; <i>Am J Psychiatry</i>, 2006, 163(7):1298.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/16816247/pubmed\" target=\"_blank\" id=\"16816247\">16816247</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thinn SS, Liew E, May AL, et al, &ldquo;Reversible Delayed Onset Olanzapine-Associated Leukopenia and Neutropenia in a Clozapine-Naive Patient on Concomitant Depot Antipsychotic,&rdquo; <i>J Clin Psychopharmacol</i>, 2007, 27(4):394-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/17632225/pubmed\" target=\"_blank\" id=\"17632225\">17632225</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tsuda Y, Saruwatari J, Yasui-Furukori N. Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine. <i>BMJ Open</i>. 2014;4(3):e004216.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/24595134/pubmed\" target=\"_blank\" id=\"24595134\">24595134</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Uguz F. Second-generation antipsychotics during the lactation period: a comparative systematic review on infant safety. <i>J Clin Psychopharmacol</i>. 2016;36(3):244-252.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/27028982/pubmed\" target=\"_blank\" id=\"27028982\">27028982</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ursano RJ, Bell C, Eth S, et al; Work Group on ASD and PTSD; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. <i>Am J Psychiatry</i>. 2004;161(11 Suppl):3-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/15617511/pubmed\" target=\"_blank\" id=\"15617511\">15617511</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16244481\"></a>Verhey FR, Verkaaik M, Lousberg R; Olanzapine-Haloperidol in Dementia Study group. Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results of a randomized controlled double-blind trial. <i>Dement Geriatr Cogn Disord</i>. 2006;21(1):1-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/16244481/pubmed\" target=\"_blank\" id=\"16244481\">16244481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16244481\"></a>Whitworth A, Stuppaeck C, Yazdi K, et al. Olanzapine and breast-feeding: changes of plasma concentrations of olanzapine in a breast-fed infant over a period of 5 months. <i>J Psychopharmacol</i>. 2010;24(1):121-123.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olanzapine-drug-information/abstract-text/16244481/pubmed\" target=\"_blank\" id=\"16244481\">16244481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zyprexa (olanzapine) [prescribing information]. Indianapolis, IN: Lilly USA LLC; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zyprexa Relprevv (olanzapine) [prescribing information]. Indianapolis; IN: Eli Lilly and Co; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zyprexa (olanzapine) [prescribing information]. Toronto, Ontario, Canada: Eli Lilly Canada Inc; December 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9716 Version 282.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F46537504\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709177\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F26715078\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F203157\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F203198\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F203161\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F203180\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F203162\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F203163\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F203164\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F26715079\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F26730983\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F23799571\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874938\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F203135\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F203134\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25730993\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F203206\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F203123\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F203138\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F203120\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F203191\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F203125\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F203127\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2839122\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F2839124\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F203141\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F203129\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F203119\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F203137\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F203140\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F203142\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9716|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=olanzapine-patient-drug-information\" class=\"drug drug_patient\">Olanzapine: Patient drug information</a></li><li><a href=\"topic.htm?path=olanzapine-pediatric-drug-information\" class=\"drug drug_pediatric\">Olanzapine: Pediatric drug information</a></li></ul></div></div>","javascript":null}